Mivotilate

Mivotilate

SCHEMBL8752155

Cc1csc(NC(=O)C(C(=O)OC(C)C)=C2SCS2)n1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
RAB9A P51151 8/20 0.43
NPC1 O15118 7/20 0.43
HPGD P15428 4/20 0.43
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
PKM P14618 1/20 0.43
EPHX2 P34913 1/20 0.41
HTT P42858 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
HSD17B10 Q99714 1/20 0.41
RCE1 Q9Y256 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CNR2 P34972 1/20 0.40
RECQL P46063 1/20 0.40
FFAR2 O15552 1/20 0.40
POLB P06746 1/20 0.39
GCK P35557 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9523229 0.93 MAPT (0.43) MAPTRAB9ANPC1HPGDALDH1A1
SCHEMBL8752149 0.87 ADRA1A (0.55) MAPTRAB9ANPC1HPGDALDH1A1
SCHEMBL8752175 0.86 L3MBTL1 (0.48) MAPTRAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL8752167 0.84 RAB9A (0.46) MAPTRAB9ANPC1HPGDALDH1A1
SCHEMBL9520912 0.82 MAPT (0.49) MAPTRAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL9520587 0.82 RAB9A (0.49) MAPTRAB9ANPC1HPGDALDH1A1
SCHEMBL8752169 0.81 PKM (0.48) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL9521789 0.80 CTSK (0.41) RAB9ANPC1HPGDALDH1A1SMN1; SMN2
SCHEMBL13694514 0.75 MAPT (0.55) MAPTRAB9ANPC1HPGDALDH1A1
SCHEMBL9521170 0.74 SMN1; SMN2 (0.50) MAPTRAB9ANPC1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4484426-A1 PYRIMIDO AROMATIC RING COMPOUND AND USE THEREOF IN DRUG Sunshine Lake Pharma Co., Ltd. (CN) 2025-01-01 EP claimed
US-12128044-B2 Fused tricyclic compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. (CN) 2024-10-29 US claimed
EP-3694856-B1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO LTD (CN) 2023-10-25 EP claimed
US-11773098-B2 Solid forms of a toll-like receptor modulator GILEAD SCIENCES, INC. (US) 2023-10-03 US claimed
WO-2023160527-A1 PYRIMIDO AROMATIC RING COMPOUND AND USE THEREOF IN DRUG 广东东阳光药业股份有限公司 2023-08-31 WO claimed
WO-2022156758-A1 NOVEL AMIDE PYRROLE COMPOUND AND USE THEREOF IN DRUGS 广东东阳光药业有限公司 2022-07-28 WO claimed
WO-2022143610-A1 NOVEL AMIDE PYRROLE COMPOUNDS AND USE THEREOF IN MEDICAMENTS 广东东阳光药业有限公司 2022-07-07 WO claimed
US-20220194951-A1 DIHYDROPYRIMIDINE COMPOUND AND APPLICATION THEREOF AS DRUG SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-06-23 US claimed
US-11261190-B2 Dihydropyrimidine compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-03-01 US claimed
EP-0782854-A2 Use of isopropyl-2-(1,3-dithietan-2-ylidene)-2-(N-(4-methylthiazol-2-yl)carbamoyl)acetate as a cancer chemopreventive agent Yuhan Corporation (KR) 1997-07-09 EP claimed
EP-0766560-A1 USE OF THIOKETENE DERIVATIVES FOR PREVENTING OR TREATING HEPATITIS B YUHAN CORPORATION, LTD. (KR) 1997-04-09 EP claimed
WO-1996033711-A2 USE OF THIOKETENE DERIVATIVES FOR PREVENTING OR TREATING HEPATITIS B YUHAN CORPORATION (KR) 1996-10-31 WO claimed
JP-9249564-A None JP disclosed
CN-122036801-A Crystalline forms of tenofovir alafenamide 吉利德科学公司 2026-05-15 CN disclosed
EP-3870566-B1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES INC (US) 2026-05-06 EP disclosed
EP-4234030-B1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES INC (US) 2026-04-08 EP disclosed
EP-0766560-A1 USE OF THIOKETENE DERIVATIVES FOR PREVENTING OR TREATING HEPATITIS B YUHAN CORPORATION, LTD. (KR) 1997-04-09 EP disclosed
WO-1996033711-A2 USE OF THIOKETENE DERIVATIVES FOR PREVENTING OR TREATING HEPATITIS B YUHAN CORPORATION (KR) 1996-10-31 WO disclosed
EP-0366614-B1 PHARMACEUTICALLY ACTIVE DITHIOKETENE DERIVATIVES YUHAN CORPORATION, LTD. (KR) 1993-09-01 EP disclosed
US-5103013-A For treating liver disorders YUHAN CORPORATION, LTD. (KR) 1992-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12128044-B2 Fused tricyclic compounds and uses thereof in medicine SLC10A1, CYP11B1, CYP11B2 MAPT 123/4885RAB9A 3503/4885NPC1 102/4885
US-20220194951-A1 DIHYDROPYRIMIDINE COMPOUND AND APPLICATION THEREOF AS DRUG DHODH, DPYD, SLC10A1 MAPT 63/4885RAB9A 3842/4885NPC1 660/4885
US-11773098-B2 Solid forms of a toll-like receptor modulator TLR4, TLR3, TLR6 MAPT 3799/4885RAB9A 3927/4885NPC1 2401/4885
US-11261190-B2 Dihydropyrimidine compounds and uses thereof in medicine DPYD, TPMT, SLC10A1 MAPT 181/4885RAB9A 3634/4885NPC1 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.